Fierce Pharma Asia—Merck’s collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations

Fierce Pharma September 20, 2024
Angus Liu

Merck and Daiichi Sankyo’s HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck and Eisai’s Keytruda-Lenvima combo delivered a win in liver cancer. An FDA document details shortfalls at a Granules plant in India. Plus more.

1. Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data

Merck and Daiichi Sankyo’s HER3 antibody-drug conjugate patritumab deruxtecan reported a positive phase 3 trial in EGFR-mutated non-small cell lung cancer following previous treatment with EGFR tyrosine kinase inhibitor. While progression-free survival was significantly longer in the ADC group than in the chemotherapy arm, overall survival data remained immature. Two deaths were chalked up to interstitial lung disease.

2. ESMO: Despite...

Today's Sponsors

Today's Sponsor